CGOG 2026 Day 2 | ASCO Neuroendocrine Tumors Highlights Session

CGOG 2026 Day 2 | ASCO Neuroendocrine Tumors Highlights Session

The 2026 Peking University Gastrointestinal Oncology Forum and the 16th CGOG Annual Meeting were held in Beijing from June 9–13, 2026. On June 10, the dedicated ASCO Neuroendocrine Tumors Highlights Session brought together leading Chinese experts to provide in-depth reviews of the latest advances in neuroendocrine tumor (NET) research presented at the 2026 ASCO Annual Meeting.
CGOG 2026 Day 3 | ASCO Highlights Session on Colorectal Cancer

CGOG 2026 Day 3 | ASCO Highlights Session on Colorectal Cancer

On June 11, Day 3 of the 16th Peking University Gastrointestinal Oncology Forum and CGOG Annual Meeting featured the 2026 ASCO Highlights Session on Colorectal Cancer, where leading experts provided in-depth reviews and discussions of the latest advances presented at the 2026 ASCO Annual Meeting. The session was livestreamed across multiple platforms and attracted more than 25,000 online viewers.
Learning from History: Dr. Ludovico Docimo on the Rise of Robotic Surgery in Colorectal ORs

Learning from History: Dr. Ludovico Docimo on the Rise of Robotic Surgery in Colorectal ORs

From May 15 to 17, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was held in Hangzhou. Dr. Ludovico Docimo, Professore Ordinario e Primario of the UOC of General, Minimally Invasive and Obesity Surgery at the University of Campania "Luigi Vanvitelli" (Italy), shared his view that robotic surgery will transform colorectal operating rooms, much like laparoscopy did.
From Screening to Precision MDT: Prof. Zhang Suzhan on the “China Solution” for Colorectal Cancer

From Screening to Precision MDT: Prof. Zhang Suzhan on the “China Solution” for Colorectal Cancer

On March 21, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was convened in Hangzhou, Zhejiang Province. Prof. Zhang Suzhan from the Second Affiliated Hospital, Zhejiang University School of Medicine attended the meeting and shared his insights on colorectal cancer screening, precision MDT management, and localized Chinese clinical solutions.
ESMO BC Voices From China | Real-World Study From Yunnan Cancer Hospital Identifies High-Risk Features Associated With Early Rapid Progression After First-Line CDK4/6 Inhibitor Therapy in HR+/HER2− Advanced Breast Cancer

ESMO BC Voices From China | Real-World Study From Yunnan Cancer Hospital Identifies High-Risk Features Associated With Early Rapid Progression After First-Line CDK4/6 Inhibitor Therapy in HR+/HER2− Advanced Breast Cancer

CDK4/6 inhibitors combined with endocrine therapy have become the standard first-line treatment for HR-positive/HER2-negative advanced breast cancer and have significantly improved patient outcomes. However, in real-world clinical practice, a subset of patients still experiences rapid disease progression early during treatment, suggesting the presence of more aggressive tumor biology and potential intrinsic endocrine resistance mechanisms.
Sino-French Breast Reconstruction Congress | Professor Fan Li: From “One-Size-Fits-All” Surgery to Precision Remodeling—De-escalation Strategies and the Evolving Role of Breast Surgeons in the Post-Neoadjuvant Era

Sino-French Breast Reconstruction Congress | Professor Fan Li: From “One-Size-Fits-All” Surgery to Precision Remodeling—De-escalation Strategies and the Evolving Role of Breast Surgeons in the Post-Neoadjuvant Era

Against the backdrop of Chongqing’s mountainous skyline and flowing rivers, the 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference were successfully held in Chongqing from April 15–19, 2026.